http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3998806-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4e5aca95e88bbf672b211a9427a5b8e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 |
| filingDate | 1975-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1976-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf401fa8ec9b92beed7e1e0c53b06e7c |
| publicationDate | 1976-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-3998806-A |
| titleOfInvention | α- and β-2'-Deoxy-6-R-substituted selenoguanosine compounds |
| abstract | Treatment of the α and β anomers of 2'-deoxy-6-selenoguanosine with alkyl halides, p-nitrobenzyl bromide, and 5-chloro-1-methyl-4-nitroimidazole under basic conditions has produced the desired products, which are 2'-deoxy-6-R-selenoguanosines where R is the substituent group [2-amino-6-R-seleno-9-(2-deoxy-α- and β-D-erythro-pentofuranosyl)purines] and R is preferably lower alkyl or aryl. The animal test screening indicated substantial activity for several members of this group of compounds against mouse leukemia L-1210. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4552955-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010137573-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8354524-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7982030-B2 |
| priorityDate | 1975-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.